| Chief Investigator: |
Henning Wege |
UK National Coordinator:
|
John Bridgewater |
| Overall Sponsor: |
University Medical Center Hamburg-Eppendorf |
| UK Sponsor: |
University of Birmingham |
| UK Funder: |
Cancer Research UK |
| Disease Site: |
Liver and Gallbladder |
| Trial Type: |
Clinical Trial of an Investigational Medicinal Product |
| Status: |
Closed |
| UKCRN Study ID (if applicable): |
173496 |
| Open to New Sites? |
Yes |
| Overall Recruitment Start Date: |
Feb 2014 |
| UK Recruitment Start Date: |
15 Mar 2016 |
| Anticipated Recruitment End Date: |
November 2022 |
| CRCTU Trial Management Team: |
A-Team |
| Trial Email Address: |
ACTICCA-01@trials.bham.ac.uk |
Trial Summary
ACTICCA-1 is a clinical study comparing the ‘post-surgery’ treatment of patients who have had surgery to remove cholangiocarcinoma (cancer of bile ducts in the liver) or muscle invasive gall bladder carcinoma (gall bladder cancer). One set of patients will have 24 weeks of chemotherapy (gemcitabine and cisplatin) after their surgery and one set of patients will receive 24 weeks of capecitabine tablet chemotherapy.
The main thing being compared is how long both sets of patients survive without their cancer coming back. There is currently not much research looking at this.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Trial Protocol
Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website (see the link below).
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.